Intermittent Claudication Drugs in Development Research Report 2022: Pipeline Landscape, Stages, Target, MoA, RoA, Molecule Type and Key Players – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Intermittent Claudication Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update” report has been added to ResearchAndMarkets.com’s offering.

This pipeline guide provides comprehensive information on the therapeutics under development for Intermittent Claudication (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Intermittent Claudication (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Intermittent Claudication and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 3 and 1 respectively.

Intermittent Claudication (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Intermittent Claudication (Cardiovascular).
• The pipeline guide reviews pipeline therapeutics for Intermittent Claudication (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Intermittent Claudication (Cardiovascular) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Intermittent Claudication (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Intermittent Claudication (Cardiovascular)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Intermittent Claudication (Cardiovascular).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Intermittent Claudication (Cardiovascular) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

Introduction

Report Coverage

Overview

Therapeutics Development

• Pipeline Overview
• Pipeline by Companies
• Products under Development by Companies

Therapeutics Assessment

• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type

Companies Involved in Therapeutics Development

• G. Pohl-Boskamp GmbH & Co KG
• Helixmith Co Ltd
• ID Pharma Co Ltd
• Pluristem Therapeutics Inc

Drug Profiles

• donaperminogene seltoplasmid – Drug Profile
• DVC-10101 – Drug Profile
• emiplacel – Drug Profile
• Gene Therapy for Cardiovascular, Dermatology and Neurology – Drug Profile
• nitroglycerin – Drug Profile

Dormant Projects

Discontinued Products

Product Development Milestones

Featured News & Press Releases

• Nov 12, 2018: New findings from Pluristem’s phase II IC study: PLX-PAD cells significantly improves blood glucose control (HbA1c) and reduce chronic inflammation
• Jun 12, 2018: Pluristem Reports Positive Top-Line Results from Its Multinational Phase II Intermittent Claudication Study
• Jun 04, 2018: Pluristem to Announce Top-Line Results of Its Multinational Phase II Intermittent Claudication Study on June 12, 2018
• Nov 29, 2017: Peer-Reviewed Article Published on Pluristems PLX-PAD Cells Mechanism of Action to Restore Blood Flow in Ischemic Tissue
• May 11, 2017: CHA Biotech Announces Completion of Koreas Phase II Trial in Intermittent Claudication (IC)
• Jan 12, 2017: Pluristem Completes Patient Enrollment in a Large Multinational Phase II Trial in Intermittent Claudication
• May 16, 2016: Pluristem Completes Enrollment of 150 Patients in Phase II Intermittent Claudication Trial
• Aug 17, 2015: Pluristem Granted U.S. Patent for Production Methods and Use of Placental Cell Therapy in a Range of Indications
• Nov 13, 2013: Pluristem Receives Regulatory Approval to Extend Its Phase II Study of PLX-PAD Cells in the Treatment of Intermittent Claudication to South Korea
• Oct 02, 2013: Pluristem Receives Israeli Ministry of Health Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to Israel
• Sep 16, 2013: FDA Lifts Clinical Hold of Pluristem’s Phase II Intermittent Claudication Study
• Jul 08, 2013: Pluristem’s South Korean Partner Files IND With Korean FDA for PLX Cells
• Jun 04, 2013: Pluristem To Receive Clinical-hold Notice From FDA For US Phase II Intermittent Claudication Study
• Jan 15, 2013: Pluristem Receives Approval To Expand Phase II Clinical Trial In Intermittent Claudication To Germany
• Aug 23, 2012: Pluristem Commences Phase II Clinical Trial For Intermittent Claudication Using PLX Cells

Appendix

For more information about this report visit https://www.researchandmarkets.com/r/ojsxpu

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900